SCAI

NEW DATA: 70% OF AMERICANS UNAWARE OF COMMON VASCULAR DISEASE THAT IS ONE OF THE LEADING CAUSES OF AMPUTATION

Retrieved on: 
Thursday, February 8, 2024
Pulse, Interventional radiology, Health equity, SCAI, Society for Vascular Surgery, Pain, Peripheral artery disease, MD Anderson Cancer Center, Prevalence, Interventions, SIR, University, Heart, Health, Amputation, Society, Diabetes, Heated tobacco product, Smoker, Risk, Patient, Leg, Rest, Vascular disease, Society of Interventional Radiology, PAD, Walking, MBA, Association of Black Cardiologists, Doctor of Philosophy

WASHINGTON, Feb. 8, 2024 /PRNewswire/ -- According to a new national survey released today by the PAD Pulse Alliance, 70% of Americans are unaware of peripheral artery disease (PAD) – the most common vascular disease in which leg arteries become narrowed, reducing or cutting off blood flow, contributing to 400 amputations performed each day in the United States. The top risk factors for PAD are common chronic health conditions that disproportionately impact underserved communities. Yet among Black and Hispanic adults, nearly 80% report never having a doctor or healthcare provider discuss PAD with them – underscoring the need to start the conversation.

Key Points: 
  • The top risk factors for PAD are common chronic health conditions that disproportionately impact underserved communities.
  • That's why we're encouraging anyone with leading risk factors, diabetes, high blood pressure and use of tobacco products, to know your 'three for PAD' and talk to your doctor."
  • Data from the PAD Pulse Alliance survey highlights a disconnect among people between the risk factors and their personal perceived risk of PAD.
  • Nearly eight in 10 Black and Hispanic never had a doctor or healthcare provider talk with them about PAD.

Matica Bio Appoints Life Sciences Veteran Paul Kim as Chief Executive Officer

Retrieved on: 
Monday, February 5, 2024
Science, Other Science, Biotechnology, Research, Other Manufacturing, Health, Genetics, Manufacturing, Multimedia, SCAI, CDMO, CGT, Cognate, Investment, University of California, Berkeley, Therapy, University, GMP

View the full release here: https://www.businesswire.com/news/home/20240205648112/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240205648112/en/
    Paul Kim, Matica Bio's new CEO (Photo: Business Wire)
    As incoming CEO, Kim will manage daily operations and provide strategic direction to Matica Bio as it rapidly expands its capacity and capabilities in the U.S. and Korea.
  • Yun Jeong Song, outgoing president and CEO, will take on a new role as president of Matica Holdings.
  • Kim brings to Matica Bio nearly three decades of experience across the CDMO, CRO and R&D biopharma sectors as CEO, managing director, chief business officer, managing partner and executive board member at WCCT Global, Genopis, Cobra Biologics, Cognate BioServices, and Novartis Venture Fund.
  • Kim is also the founder of Forward Equity Partners (formerly Medivate Partners), a private equity firm focused on cross-border healthcare and life sciences investments – the first ever in Korea.

Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Retrieved on: 
Monday, December 18, 2023
Blood pressure, Cardiogenic shock, AHF, Istaroxime, Windtree Therapeutics, SCAI, Therapy, Heart, Seismology, Patient, Safety, Pharmaceutical industry

WARRINGTON, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that the Company recently enrolled the first subject in its Phase 2 SEISMiC Extension Study of istaroxime in the treatment of early cardiogenic shock. Study results are expected in mid-2024.

Key Points: 
  • The study of hospitalized patients with early cardiogenic shock (SCAI Stage B) due to acute heart failure (AHF) will evaluate two dose regimens of istaroxime compared to placebo.
  • In the previous SEISMiC study in early cardiogenic shock, patients were infused with drug or placebo for 24 hours.
  • The Company is also progressing the start-up of a parallel study in more severe, SCAI Stage C cardiogenic shock patients.
  • The istaroxime cardiogenic shock SCAI Stage C study is expected to enroll up to 20 subjects with SCAI Stage C cardiogenic shock due to AHF.

Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates

Retrieved on: 
Thursday, November 9, 2023
Cardiogenic shock, Research, LIKE, Therapy, Security (finance), Extension, Seismology, Patient, Insurance, HEART, Conference, SCAI, Patent, Pharmaceutical industry, Cryptocurrency, Windtree Therapeutics

WARRINGTON, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2023 and provided key business updates.

Key Points: 
  • WARRINGTON, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2023 and provided key business updates.
  • “During the third quarter, we initiated our plan to move the istaroxime program in cardiogenic shock to Phase 3 readiness by advancing two clinical trials.
  • Research and development expenses were $2.1 million for the third quarter of 2023, compared to $1.5 million for the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $2.6 million, compared to $2.7 million for the third quarter of 2022.

"AI and Innovation: a creative revolution in business?" Publication of a new book by SKEMA's professor, Margherita Pagani

Retrieved on: 
Wednesday, October 11, 2023
European Economic and Social Committee, Royal Holloway, University of London, EESC, Intelligence, SCAI, Routledge, University, Bayes Business School, Artificial intelligence, Creativity, Publication, Consumer, Medical device, Management, AI, Marketing

PARIS, Oct. 11, 2023 /PRNewswire/ -- In her new book, Margherita Pagani explores the interaction between artificial intelligence and business creativity.

Key Points: 
  • PARIS, Oct. 11, 2023 /PRNewswire/ -- In her new book, Margherita Pagani explores the interaction between artificial intelligence and business creativity.
  • "Artificial Intelligence for Business Creativity" examines the extent to which AI is capable of supporting the creative process within businesses.
  • Professor of artificial intelligence in marketing, Margherita Pagani is director of the SKEMA Centre for Artificial Intelligence research laboratory.
  • A world-renowned and award-winning researcher, her publications in top international journals focus on the impact of AI on consumer behavior and on digital ecosystems.

"AI and Innovation: a creative revolution in business?" Publication of a new book by SKEMA's professor, Margherita Pagani

Retrieved on: 
Wednesday, October 11, 2023
European Economic and Social Committee, Royal Holloway, University of London, EESC, Intelligence, SCAI, Routledge, University, Bayes Business School, Artificial intelligence, Creativity, Publication, Consumer, Medical device, Management, AI, Marketing

PARIS, Oct. 11, 2023 /PRNewswire/ -- In her new book, Margherita Pagani explores the interaction between artificial intelligence and business creativity.

Key Points: 
  • PARIS, Oct. 11, 2023 /PRNewswire/ -- In her new book, Margherita Pagani explores the interaction between artificial intelligence and business creativity.
  • "Artificial Intelligence for Business Creativity" examines the extent to which AI is capable of supporting the creative process within businesses.
  • Professor of artificial intelligence in marketing, Margherita Pagani is director of the SKEMA Centre for Artificial Intelligence research laboratory.
  • A world-renowned and award-winning researcher, her publications in top international journals focus on the impact of AI on consumer behavior and on digital ecosystems.

FinPay Names Newest Advisory Board Member, Bradley F. Sorte

Retrieved on: 
Tuesday, September 26, 2023
Slate, Psychology, Florida Atlantic University, Bachelor of Science in Nursing, Kaplan University, Partnership, Factitious disorder, Rice University, Marketing, Young Presidents' Organization, SCAI, COVID-19, Intelligence, Research, Privacy, Atlantic University, Advisory board, Social work, Business administration, Publication, Patient, The New York Times, Caron, Artificial intelligence, MSW, Entrepreneurship, Financial management, Family, United Arab Emirates, YPO, Pharmaceutical industry, Management, Nursing, Fran

PHILADELPHIA, Sept. 26, 2023 /PRNewswire/ -- FinPay LLC , a recognized leader in patient engagement and financial management announced today the addition of Brad Sorte as the newest member of the FinPay Advisory Board.

Key Points: 
  • PHILADELPHIA, Sept. 26, 2023 /PRNewswire/ -- FinPay LLC , a recognized leader in patient engagement and financial management announced today the addition of Brad Sorte as the newest member of the FinPay Advisory Board.
  • We are delighted to have Brad Sorte join our Advisory Board at FinPay, stated Tim Kowalski, President & CEO of FinPay.
  • "We are delighted to have Brad Sorte join our Advisory Board at FinPay," stated Tim Kowalski, President and CEO of FinPay.
  • "I am excited to join FinPay's Advisory Board to continue my work in addiction treatment."

Cardiovascular Organizations Pursue New, Independent Medical Board

Retrieved on: 
Thursday, September 21, 2023
CME, Learning, ACC, Cardiac electrophysiology, Society, FHRS, Internal medicine, HRS, American Heart Association, American Board of Medical Specialties, ABMS, SCAI, American Board of Internal Medicine, FACC, Cardiology, Continuing medical education, Doctor of Philosophy, AHA, Certification, Organization, Medical specialty, American Board of Commissioners for Foreign Missions, New Board, Patient, Physician, Heart Failure Society of America, Knowledge, American College, Maintenance of Certification, Maintenance, Nursing, MD

WASHINGTON, Sept. 21, 2023 /PRNewswire/ -- Many of the nation's most prominent cardiovascular organizations, representing tens of thousands of physicians, unite today to pursue the creation of a new Board for cardiovascular medicine. The proposed new Board would be independent of the American Board of Internal Medicine, where the cardiology certification process currently exists. Collectively, the American College of Cardiology (ACC), Heart Failure Society of America (HFSA), Heart Rhythm Society (HRS) and Society for Cardiovascular Angiography & Interventions (SCAI) are working together to submit a new Board application, with potential for additional consortium members to join.

Key Points: 
  • WASHINGTON, Sept. 21, 2023 /PRNewswire/ -- Many of the nation's most prominent cardiovascular organizations, representing tens of thousands of physicians, unite today to pursue the creation of a new Board for cardiovascular medicine.
  • The proposed new Board would be independent of the American Board of Internal Medicine, where the cardiology certification process currently exists.
  • "We know that the cardiovascular community is ready for an independent, self-governed entity, and we are proud to develop this new Board with cardiologists and cardiology organizations at the helm."
  • Together, the consortium will submit an application to the American Board of Medical Specialties (ABMS), requesting an independent medical Board for cardiovascular medicine to pursue a new competency-based approach to continuous certification—one that harnesses the knowledge, skills and attitudes required to sustain professional excellence and care for cardiovascular patients effectively.

RAMPART IC Announces the Addition of Rob Williamson to Its Board of Managers

Retrieved on: 
Saturday, September 2, 2023
Radiation, Intervention, International Atomic Energy Agency, E pluribus unum, SCAI, Catheter, IC, Multimedia, Foxhollow School, Interventions, Medtronic, Physician, LW, Pharmaceutical industry, Management, Medical imaging, Nursing, Covidien, Rampart, M1128

BIRMINGHAM, Ala., Sept. 2, 2023 /PRNewswire-PRWeb/ -- RAMPART IC has named Rob Williamson to its Board of Managers. Rob has spent the last 25 years in the medical devices industry, with companies such as Medtronic, Covidien, ev3, FoxHollow, and Bard. Most recently Rob served as the vice president of sales for Shockwave Medical where he built a sales team of more than 300 field reps and achieved more than $500M in revenue. Rob brings a wealth of start-up, commercial, and board experience to Rampart IC.

Key Points: 
  • BIRMINGHAM, Ala., Sept. 2, 2023 /PRNewswire-PRWeb/ -- RAMPART IC has named Rob Williamson to its Board of Managers.
  • "The Rampart team is excited and honored to have Rob join our Board of Managers and leadership team," said Rampart President and CEO Tom Livingston.
  • "The Rampart team is excited and honored to have Rob join our Board of Managers and leadership team," said Rampart President and CEO Tom Livingston.
  • "The Rampart team is excited and honored to have Rob join our Board of Managers and leadership team," said Rampart President and CEO Tom Livingston.

Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates

Retrieved on: 
Monday, August 7, 2023
Exercise, AHF, Patent, Insurance, Rockwell Medical, Cardiogenic shock, SCAI, HEART, Research, Heart, LIKE, Patient, Anemia, Average cost, European Patent Convention, Toxicology, European Patent Office, Security (finance), Therapy, Family, Seismology, Pharmaceutical industry, Life insurance, Cryptocurrency, Windtree Therapeutics

WARRINGTON, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported financial results for the second quarter ended June 30, 2023 and provided key business updates.

Key Points: 
  • Company plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic shock in Q3;
    WARRINGTON, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported financial results for the second quarter ended June 30, 2023 and provided key business updates.
  • For the second quarter ended June 30, 2023, the Company reported an operating loss of $6.8 million, compared to an operating loss of $17.5 million in the second quarter of 2022.
  • Research and development expenses were $1.8 million for the second quarter of 2023, compared to $3.0 million for the second quarter of 2022.
  • General and administrative expenses for the second quarter of 2023 were $2.4 million, compared to $2.9 million for the second quarter of 2022.